Cellectis (CLLS) Gross Profit (QoQ) (2015 - 2023)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 154.72% |
| Sep 30, 2023 | -272.36% |
| Jun 30, 2023 | 163.08% |
| Mar 31, 2023 | -555.07% |
| Dec 31, 2022 | 122.32% |
| Sep 30, 2022 | -119.63% |
| Jun 30, 2022 | -23.59% |
| Mar 31, 2022 | 1,934.28% |
| Dec 31, 2021 | 92.26% |
| Sep 30, 2021 | -55.88% |
| Jun 30, 2021 | -103.31% |
| Mar 31, 2021 | 449.47% |
| Dec 31, 2020 | -204.39% |
| Sep 30, 2020 | 43.94% |
| Jun 30, 2020 | -106.43% |
| Mar 31, 2020 | 3,804.48% |
| Dec 31, 2019 | -129.05% |
| Sep 30, 2019 | 1,155.49% |
| Jun 30, 2019 | -25.11% |
| Mar 31, 2019 | 81.45% |
| Dec 31, 2018 | 552.63% |
| Sep 30, 2018 | -99.15% |
| Jun 30, 2018 | -17.78% |
| Mar 31, 2018 | -9.39% |
| Dec 31, 2017 | 8.54% |
| Sep 30, 2017 | 2,558.03% |
| Jun 30, 2017 | -96.59% |
| Mar 31, 2017 | -19.16% |
| Dec 31, 2016 | -30.53% |
| Sep 30, 2016 | 3,057.35% |
| Jun 30, 2016 | -95.21% |
| Mar 31, 2016 | -79.23% |
| Dec 31, 2015 | 330.03% |
| Sep 30, 2015 | 5.43% |
| Jun 30, 2015 | -15.21% |